Vectura | Sustainability Performance
Develops and markets inhalation products and devices for respiratory diseases.
1997
United Kingdom
201 - 500 employees
Pharmaceuticals
$100M - 500M in revenue
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#3448
Overallⓘ#387
in United Kingdomⓘ#83
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Controversy level
- The company, a developer of inhaled medicines for respiratory diseases such as asthma and chronic obstructive pulmonary disease, was acquired by tobacco company Philip Morris International in 2021, a takeover widely condemned by the medical and publichealth community (including the British Medical Association, the European Respiratory Society and Asthma UK) as a profound conflict of interest, since a cigarette maker would profit from treating diseases caused by smoking, leading several research bodies and hospitals to cut ties with the company.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
2-3
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.